News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • India will continue bilateral trade talks with the U.S. after Washington imposed a 10% tariff on about 55% of Indian exports.
  • Brazil refused visas for two U.S. officials, raising bilateral tensions ahead of Brazil's October presidential election.
  • Analysts pitch tactical buy trades across sectors: fintech (SoFi), gaming (Take-Two), semiconductors (AMD), aviation (Joby), and small caps.
  • AMD is positioned to benefit from rising AI infrastructure demand, prompting a bullish trade setup despite rich valuation.
  • Broadcasters like Gray Media are being bought ahead of expected political-ad spending into the 2026 cycle.
  • Royalty names (Gold Royalty, Kimbell) are recommended for improving cash flow and potential re-rating as production and acquisitions accelerate.

Latest Articles

CVR Energy: Play the Macro Tailwind, Respect the Margin Trap

CVR Energy: Play the Macro Tailwind, Respect the Margin Trap

CVR Energy (CVI) is a leveraged refining complex with renewable diesel and fertilizer businesses. Margins have been weak and profitability remains negative, but macro-driven widening crack spreads and recent technical weakness create a defined risk-reward swing trade. Entry $31.50, stop $28.00, target $38.00 — mid-term (45 trading days), medium ris…

Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026

Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026

Atea Pharmaceuticals announced Phase 1 data indicating their fixed-dose combination regimen of bemnifosbuvir and ruzasvir (BEM/RZR) for hepatitis C virus (HCV) treatment displays a low risk of drug-drug interactions, supporting its use alongside common medications such as omeprazole and rosuvastatin. Additionally, preclinical results for AT-587, a …

Dycom Industries, Inc. Reports Record First Quarter Results and Raises Full Year Fiscal 2027 Outlook

Dycom Industries, Inc. Reports Record First Quarter Results and Raises Full Year Fiscal 2027 Outlook

Dycom Industries, Inc. reported record first quarter fiscal 2027 results with contract revenues of $1.965 billion, a 56.1% increase from the prior year, strong profitability, and a backlog growth of 46.5%. The company raised its full-year fiscal 2027 outlook and announced the acquisition of National Technology Integrators to enhance its Building Sy…

BrewDog Turns This Summer’s Global Football Tournament into a Nationwide Celebration of Beer, Bars and Big Match Moments

BrewDog Turns This Summer’s Global Football Tournament into a Nationwide Celebration of Beer, Bars and Big Match Moments

BrewDog, a leading UK craft beer brand owned by Tilray Brands, is launching a nationwide summer campaign called 'Underdog' to coincide with the global football tournament. The campaign includes a 'Win a Year of Beer' promotion across major UK retailers, in-bar football watch parties, themed events, and extensive digital and retail activations. This…

Satellos to Participate in Upcoming Investor Conferences

Satellos to Participate in Upcoming Investor Conferences

Satellos Bioscience Inc., a clinical-stage biotech focused on developing treatments for degenerative muscle diseases, will participate in upcoming investor conferences in June 2026. The company will present updates on its lead drug candidate, SAT-3247, currently in Phase II trials for Duchenne muscular dystrophy (DMD). SAT-3247 targets the AAK1 pro…

Sagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASH

Sagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASH

Sagimet Biosciences announced the presentation of two posters at EASL 2026 showcasing Phase 1 clinical data on the combination of denifanstat and resmetirom for treatment of metabolic dysfunction-associated steatohepatitis (MASH). The combination was generally well-tolerated and demonstrated rapid reductions in total and LDL cholesterol, suggesting…

Aurora Mobile's GPTBots.ai Upgrades AI Agents from Chat to Execution

Aurora Mobile's GPTBots.ai Upgrades AI Agents from Chat to Execution

Aurora Mobile Limited announced major upgrades to its enterprise AI platform GPTBots.ai, enhancing its capabilities from conversational AI to active execution within business workflows. Key improvements include a knowledge graph-based understanding system, advanced multi-agent workflow execution, and strengthened governance for secure production de…

Rocket Lab Achieves Milestone for Missile Defense Constellation, Passes System Requirements Review for SDA Tracking Layer Tranche 3

Rocket Lab Achieves Milestone for Missile Defense Constellation, Passes System Requirements Review for SDA Tracking Layer Tranche 3

Rocket Lab USA, Inc. has successfully passed the System Requirements Review for the Space Development Agency's Tracking Layer Tranche 3 constellation, confirming their proposed solution meets operational requirements for missile warning and defense satellites. This milestone supports a contract valued at approximately $816 million, adding to Rocket…

Climb Announces North American Distribution Partnership with Quantum

Climb Announces North American Distribution Partnership with Quantum

Climb Global Solutions, an international specialty technology distributor, announced a new North American distribution partnership with Quantum Corporation, a leader in data protection and management solutions. This partnership expands access to Quantum's product portfolio, helping resellers address complex data challenges with high-performance sto…

G-III Apparel Group Declares Quarterly Dividend

G-III Apparel Group Declares Quarterly Dividend

G-III Apparel Group, Ltd., a global fashion leader with a diverse brand portfolio, declared a quarterly cash dividend of $0.10 per share payable to shareholders on July 8, 2026. The announcement reflects the company's ongoing commitment to returning value to investors amid its extensive licensing and retail operations in the fashion sector.

Intchains Group to Present at the Noble Capital Markets Emerging Growth Virtual Equity Conference on June 3-4

Intchains Group to Present at the Noble Capital Markets Emerging Growth Virtual Equity Conference on June 3-4

Intchains Group Limited, a Nasdaq-listed company specializing in altcoin mining and staking, announced its participation in the Noble Capital Markets Emerging Growth Virtual Equity Conference scheduled for June 3-4, 2026. The company will present its business strategy and engage with investors through one-on-one meetings during the virtual event.

Tonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of Clinical Immunology

Tonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of Clinical Immunology

Tonix Pharmaceuticals announced the publication of Phase 1 clinical data for TNX-1500, a novel Fc-modified anti-CD40L monoclonal antibody designed to prevent organ transplant rejection and treat autoimmune diseases. The study demonstrated favorable safety, tolerability, and pharmacodynamics in healthy adults, supporting the planned Phase 2 investig…

Lantronix Announces Preliminary Inclusion in Russell 3000® Index

Lantronix Announces Preliminary Inclusion in Russell 3000® Index

Lantronix Inc., a provider of Edge AI and Industrial IoT solutions, announced its preliminary addition to the Russell 3000 Index as part of the 2026 Russell indexes reconstitution. This inclusion is reflective of the company's strategic repositioning towards higher-growth and higher-value markets and is expected to enhance its visibility to institu…

BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting

BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting

BioCryst Pharmaceuticals announces seven abstracts from its hereditary angioedema (HAE) portfolio to be presented at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting. The data focus on ORLADEYO (berotralstat), the first oral prophylactic therapy for HAE, and navenibart, an investigational monoclonal antibody for attack pr…

Korro to Present at the 2026 Jefferies Global Healthcare Conference

Korro to Present at the 2026 Jefferies Global Healthcare Conference

Korro Bio, a biopharmaceutical company specializing in RNA editing genetic medicines via its OPERA platform, announced CEO Ram Aiyar will present at the 2026 Jefferies Global Healthcare Conference. The presentation highlights Korro's innovative approach to developing treatments for rare and prevalent diseases by precisely editing RNA to enhance the…

NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Becomes First Commercial Site to Deploy Zeta Surgical's FDA-Cleared Zeta TMS Navigation System

NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Becomes First Commercial Site to Deploy Zeta Surgical's FDA-Cleared Zeta TMS Navigation System

NRx Pharmaceuticals announced that its subsidiary, HOPE Therapeutics, has become the first commercial site to use Zeta Surgical's FDA-cleared Zeta TMS Navigation System at its West Palm Beach clinic. The system integrates AI-powered, sub-millimetric image guidance to improve precision in Transcranial Magnetic Stimulation (TMS) treatment for major d…